193 related articles for article (PubMed ID: 10749870)
41. Transforming growth factor-beta induces selective increase of proteoglycan production and changes in the copolymeric structure of dermatan sulphate in human skin fibroblasts.
Westergren-Thorsson G; Schmidtchen A; Särnstrand B; Fransson LA; Malmström A
Eur J Biochem; 1992 Apr; 205(1):277-86. PubMed ID: 1555588
[TBL] [Abstract][Full Text] [Related]
42. Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II.
Giri TK; Tollefsen DM
Blood; 2006 Apr; 107(7):2753-8. PubMed ID: 16339402
[TBL] [Abstract][Full Text] [Related]
43. Expression of small extracellular chondroitin/dermatan sulfate proteoglycans is differentially regulated in human endothelial cells.
Nelimarkka L; Kainulainen V; Schönherr E; Moisander S; Jortikka M; Lammi M; Elenius K; Jalkanen M; Järveläinen H
J Biol Chem; 1997 May; 272(19):12730-7. PubMed ID: 9139731
[TBL] [Abstract][Full Text] [Related]
44. Biglycan organizes collagen VI into hexagonal-like networks resembling tissue structures.
Wiberg C; Heinegård D; Wenglén C; Timpl R; Mörgelin M
J Biol Chem; 2002 Dec; 277(51):49120-6. PubMed ID: 12354766
[TBL] [Abstract][Full Text] [Related]
45. Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain. Implication for thrombin inhibition.
Ciaccia AV; Monroe DM; Church FC
J Biol Chem; 1997 May; 272(22):14074-9. PubMed ID: 9162031
[TBL] [Abstract][Full Text] [Related]
46. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice.
Vicente CP; He L; Pavão MS; Tollefsen DM
Blood; 2004 Dec; 104(13):3965-70. PubMed ID: 15315969
[TBL] [Abstract][Full Text] [Related]
47. Structural heterogeneity of dermatan sulfate chains: correlation with heparin cofactor II activating properties.
Denti A; Sini P; Tira ME; Balduini C
Thromb Res; 1995 Jul; 79(2):187-98. PubMed ID: 7676405
[TBL] [Abstract][Full Text] [Related]
48. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
Tran TH; Duckert F
Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
[TBL] [Abstract][Full Text] [Related]
49. Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.
He L; Giri TK; Vicente CP; Tollefsen DM
Blood; 2008 Apr; 111(8):4118-25. PubMed ID: 18281504
[TBL] [Abstract][Full Text] [Related]
50. Dermatan sulfate in tunicate phylogeny: order-specific sulfation pattern and the effect of [→4IdoA(2-sulfate)β-1→3GalNAc(4-sulfate)β-1→] motifs in dermatan sulfate on heparin cofactor II activity.
Kozlowski EO; Lima PC; Vicente CP; Lotufo T; Bao X; Sugahara K; Pavão MS
BMC Biochem; 2011 May; 12():29. PubMed ID: 21619699
[TBL] [Abstract][Full Text] [Related]
51. The role of decorin and biglycan dermatan sulfate chain(s) in fibrosis-affected fascia.
Koźma EM; Wisowski G; Kusz D; Olczyk K
Glycobiology; 2011 Oct; 21(10):1301-16. PubMed ID: 21543445
[TBL] [Abstract][Full Text] [Related]
52. Differential expression of the small chondroitin/dermatan sulfate proteoglycans decorin and biglycan after injury of the adult rat brain.
Stichel CC; Kappler J; Junghans U; Koops A; Kresse H; Müller HW
Brain Res; 1995 Dec; 704(2):263-74. PubMed ID: 8788923
[TBL] [Abstract][Full Text] [Related]
53. Source of peritoneal proteoglycans. Human peritoneal mesothelial cells synthesize and secrete mainly small dermatan sulfate proteoglycans.
Yung S; Thomas GJ; Stylianou E; Williams JD; Coles GA; Davies M
Am J Pathol; 1995 Feb; 146(2):520-9. PubMed ID: 7856761
[TBL] [Abstract][Full Text] [Related]
54. Structural varieties of small proteoglycans in human spinal ligament.
Yukawa M; Takagaki K; Itabashi T; Ueyama K; Harata S; Endo M
Connect Tissue Res; 2001; 42(3):209-22. PubMed ID: 11913492
[TBL] [Abstract][Full Text] [Related]
55. Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases.
Langford-Smith KJ; Mercer J; Petty J; Tylee K; Church H; Roberts J; Moss G; Jones S; Wynn R; Wraith JE; Bigger BW
J Inherit Metab Dis; 2011 Apr; 34(2):499-508. PubMed ID: 21170681
[TBL] [Abstract][Full Text] [Related]
56. Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.
Sarilla S; Habib SY; Tollefsen DM; Friedman DB; Arnett DR; Verhamme IM
Anal Biochem; 2010 Nov; 406(2):166-75. PubMed ID: 20670608
[TBL] [Abstract][Full Text] [Related]
57. Modulation of sulfated glycosaminoglycan and small proteoglycan synthesis by the extracellular matrix.
Wegrowski Y; Gillery P; Kotlarz G; Perreau C; Georges N; Maquart FX
Mol Cell Biochem; 2000 Feb; 205(1-2):125-31. PubMed ID: 10821430
[TBL] [Abstract][Full Text] [Related]
58. Role of lysine 173 in heparin binding to heparin cofactor II.
Whinna HC; Blinder MA; Szewczyk M; Tollefsen DM; Church FC
J Biol Chem; 1991 May; 266(13):8129-35. PubMed ID: 1902471
[TBL] [Abstract][Full Text] [Related]
59. Recombinant dermatan sulfate is a potent activator of heparin cofactor II-dependent inhibition of thrombin.
Tykesson E; Maccarana M; Thorsson H; Liu J; Malmström A; Ellervik U; Westergren-Thorsson G
Glycobiology; 2019 Jun; 29(6):446-451. PubMed ID: 30869126
[TBL] [Abstract][Full Text] [Related]
60. Heparin cofactor II modulates the response to vascular injury.
Tollefsen DM
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):454-60. PubMed ID: 17194895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
